WATERTOWN, MA, Selecta Biosciences, a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, announced today that it has completed a $38 million Series E equity financing. more...
VALENCIA, CA, SetPoint Medical, a biomedical technology company developing a bioelectronic therapy for inflammatory diseases, announced today that it has secured $15 million in an extension to its Series C equity financing. more...